Epirubicin: Action as an Anthracycline

Epirubicin (brand names Farmorubicin and generics) is an anthracycline cytostatic agent from the same substance class as doxorubicin and is used in oncology as an important component of various chemotherapy protocols. It is a 4-epimer of doxorubicin and differs from it in the stereochemistry of the hydroxyl group on the amino sugar. This structural modification has clinically relevant consequences: epirubicin has a more favorable side effect profile with lower cardiotoxicity compared to comparable antitumor efficacy. In Germany, epirubicin has been established since the 1980s and is used primarily in breast cancer, gastric cancer, and urological tumors.

Anthracyclines are among the oldest and simultaneously most effective cytostatic agents in oncology. Their use requires extensive experience because of characteristic side effects, especially cumulative cardiotoxicity, bone marrow suppression, and typical complications such as nausea, vomiting, and mucous membrane damage. Epirubicin is administered exclusively in specialized oncological centers where therapy protocols, supportive care, and follow-up monitoring are coordinated according to guidelines.

Mechanism of Action

Epirubicin exerts its cytostatic effect through multiple mechanisms. The most important is the inhibition of topoisomerase II, an enzyme that catalyzes and closes double-strand breaks during DNA replication and transcription. Epirubicin stabilizes the topoisomerase II DNA complex in a double-strand break state, leading to accumulation of DNA damage and ultimately cell death. Additionally, epirubicin intercalates into the DNA double helix and disrupts the normal function of DNA polymerase and RNA polymerase.

Another mechanism is the generation of free oxygen radicals through reduction in the respiratory chain. These radicals damage DNA, proteins, and membranes and contribute to the antitumor effect, but are also largely responsible for the cardiotoxic effect. In heart muscle, the antioxidative capacity is lower than in other tissues, which explains the specific susceptibility of cardiac muscle cells.

Pharmacokinetically, epirubicin is rapidly distributed to tissues following intravenous administration. The elimination half-life is approximately 30 to 35 hours. Metabolism occurs predominantly hepatically, with an active metabolite epirubicinol and several glucuronides. Excretion is primarily biliary and fecal, to a minor degree renal. In hepatic insufficiency, dose adjustment is therefore necessary. Epirubicin can leak from the intravenous access into surrounding tissue during administration and cause severe tissue necrosis, which is why the intravenous access must be carefully checked before and during infusion.

Indications

• Breast cancer: in adjuvant chemotherapy after surgery, in neoadjuvant therapy before surgery, in palliative therapy for metastatic disease
• Gastric cancer: as a component of combination protocols such as ECF, ECX, EOX
• Esophageal cancer: in specific protocols
• Urogenital tumors: non-muscle-invasive bladder cancer as intravesical therapy after transurethral resection for recurrence prevention
• Soft tissue sarcoma: in specific protocols
• Malignant lymphomas: in individual protocols, doxorubicin or daunorubicin are usually preferred
• Small cell and non-small cell lung cancer: in individual indications and trials

Epirubicin is often used in combination regimens with other cytostatic agents such as 5-fluorouracil, cyclophosphamide, cisplatin, or capecitabine, as the mechanisms of action complement each other.

Dosage and Administration

Breast cancer adjuvant: Standard dose 90 to 100 mg per m² every 3 weeks, typically over 4 to 6 cycles, often as part of an FEC regimen (5-FU, epirubicin, cyclophosphamide).

Gastric cancer (ECF): Epirubicin 50 mg per m² every 3 weeks, in combination with cisplatin and 5-fluorouracil.

Intravesical therapy: 50 to 80 mg in 50 ml NaCl solution intravesically, once weekly for 4 to 8 weeks, then monthly.

Cumulative maximum dose: 900 mg per m², risk of irreversible cardiotoxicity increases significantly above this threshold.

Administration: exclusively intravenous as bolus or short infusion over 5 to 30 minutes into a secure access. In case of extravasation, immediate stop, aspiration of remaining volume, local cooling, if necessary antidote with dexrazoxan or DMSO.

Renal insufficiency: dose adjustment generally not required. Hepatic insufficiency: with bilirubin increase from 1.5 mg per dl dose reduction to 50 percent, at higher values to 25 percent or pause.

Important: clinical assessment before each cycle, complete blood count, liver values, if applicable echocardiography to assess left ventricular function.

Side Effects

Very common: Bone marrow suppression with neutropenia, thrombocytopenia and anemia (maximum after 10 to 14 days, recovery after 21 days), nausea, vomiting (varying severity depending on dose and individual risk profile), mucositis and stomatitis, alopecia (usually reversible), fatigue, red coloration of urine (due to the active ingredient itself, harmless).

Common: Local reactions such as phlebitis at the injection site, diarrhea, esophagitis, hyperuricemia, allergic skin reactions.

Cardiotoxicity: Cumulative dose-related cardiomyopathy with heart failure, significantly increased risk above 900 mg per m². Acute cardiac side effects such as tachycardia, arrhythmias can occur. With risk profile or higher prior anthracycline treatment, echocardiography for risk assessment.

Occasionally to rare: Secondary leukemia, especially with prolonged use, liver toxicity, conjunctivitis, tearing, hyperpigmentation of skin and nails, hand-foot syndrome (more common with doxorubicin).

In case of extravasation: Severe tissue necrosis requiring surgical debridement. Immediate therapy with dexrazoxan or other antidotes.

Drug Interactions

• Other cardiotoxic substances (doxorubicin, trastuzumab, mediastinal radiation): additive cardiotoxicity, observe cumulative doses.
• CYP3A4 inhibitors (ketoconazole, erythromycin, ritonavir): increased epirubicin levels, caution advised.
• CYP3A4 inducers (rifampicin, carbamazepine, phenytoin): reduced levels, efficacy may be impaired.
• Other myelosuppressive substances: additive bone marrow suppression.
• Live vaccines: contraindicated during therapy and for several months thereafter.
• Cimetidine: increases epirubicin levels, avoid combination.
• Trastuzumab: cumulative cardiotoxicity, plan sequence and monitoring carefully.

Special Precautions

Pregnancy: Contraindicated due to embryotoxic and teratogenic effects. Effective contraception during and for at least 6 months after treatment completion. Breast-feeding: Contraindicated.

Children: Established in specialized pediatric oncology settings.

Contraindications: Known hypersensitivity, severe bone marrow depression, severe cardiomyopathy, recent myocardial infarction, severe hepatic insufficiency, concurrent live vaccination.

Before therapy: Echocardiography with left ventricular ejection fraction (LVEF), ECG, complete blood count, liver and kidney values, detailed history for cardiac preexisting conditions, pregnancy status.

During therapy: Regular echocardiography (before each cycle or at least every 2 to 3 cycles), complete blood count before each cycle, liver and kidney values, clinical follow-up assessment.

Before each administration: Assurance of intravenous access, antiemetic prophylaxis, if applicable growth factors in case of neutropenia risk.

Lifestyle: Infection protection with hygiene, balanced nutrition, adequate fluid intake. Avoid alcohol, avoid physical overexertion during the aplasia phase.

Driving ability: Often restricted with fatigue, dizziness and accompanying symptoms, individual assessment required.

You May Also Be Interested In

• Doxorubicin, classic anthracycline in oncology
• Cyclophosphamide, alkylating agent in combination protocols
• 5-Fluorouracil, pyrimidine analog in combination chemotherapy
• Trastuzumab, anti-HER2 antibody in breast cancer
• Dexrazoxan, cardioprotective agent and antidote in anthracycline extravasation

Frequently Asked Questions

Sources

• Gelbe Liste, Epirubicin active ingredient profile
• BfArM, Federal Institute for Drugs and Medical Devices
• German Society for Hematology and Medical Oncology (DGHO)
• AWMF S3 Guidelines for Breast Cancer, Gastric Cancer and Sarcomas